References
- Silvey M, Brandão LR. Risk Factors, Prophylaxis, and Treatment of
Venous Thromboembolism in Congenital Heart Disease
Patients. Front Pediatr . 2017;5:146. Published 2017 Jun 19.
doi:10.3389/fped.2017.00146
- Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment
of thrombosis in pediatric and congenital heart disease: a scientific
statement from the American Heart Association [published correction
appears in Circulation. 2014 Jan 14;129(2):e23]. Circulation .
2013;128:2622-2703. doi:10.1161/01.cir.0000436140.77832.7a
- Velleca A, Shullo MA, Dhital K et al. The International Society for
Heart and Lung Transplantation (ISHLT) Guidelines for the Care of
Heart Transplant Recipients, The Journal of Heart and Lung
Transplantation, 2022, ISSN 1053-2498,
https://doi.org/10.1016/j.healun.2022.09.023.
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy
and safety of new oral anticoagulants with warfarin in patients with
atrial fibrillation: a meta-analysis of randomised trials. Lancet.
2014;383:955-962. doi:10.1016/S0140-6736(13)62343-0
- Alcalai R, Butnaru A, Moravsky G, et al. Apixaban vs. warfarin in
patients with left ventricular thrombus: a prospective multicentre
randomized clinical trial‡. Eur Heart J Cardiovasc
Pharmacother . 2022;8:660-667. doi:10.1093/ehjcvp/pvab057
- Kumar D, Warsha FNU, Helmstetter N, Gupta V. Efficacy and safety of
direct oral anticoagulants for treatment of left ventricular thrombus;
a systematic review. Acta Cardiol. 2021;76:825-829.
doi:10.1080/00015385.2021.1901024
- Kazerouninia A, Georgekutty J, Kendsersky P, et al. A Multisite
Retrospective Review of Direct Oral Anticoagulants Compared to
Warfarin in Adult Fontan Patients [published online ahead of print,
2022 Jan 13]. Cardiovasc Drugs Ther .
2022;10.1007/s10557-021-07298-5. doi:10.1007/s10557-021-07298-5
- Mills K, Hill C, King M, et al. Just DOAC: Use of direct-acting oral
anticoagulants in pediatrics [published online ahead of print, 2023
Jan 5]. Am J Health Syst Pharm . 2023;zxac387.
doi:10.1093/ajhp/zxac387
- Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).
Biomedicines. 2021 Apr 21;9:445. doi: 10.3390/biomedicines9050445.
PMID: 33919121; PMCID: PMC8143174.
- O’Brien SH, Li D, Mitchell LG, et al. PREVAPIX-ALL: Apixaban Compared
to Standard of Care for Prevention of Venous Thrombosis in Paediatric
Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb
Haemost . 2019;119:844-853. doi:10.1055/s-0039-1679938
- Payne RM, Burns KM, Glatz AC, et al. A multi-national trial of a
direct oral anticoagulant in children with cardiac disease: Design and
rationale of the Safety of ApiXaban On Pediatric Heart disease On the
preventioN of Embolism (SAXOPHONE) study. Am Heart J .
2019;217:52-63. doi:10.1016/j.ahj.2019.08.002
- Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Apixaban Versus
Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart
Disease : A Population-Based Study. Ann Intern Med .
2022;175:1506-1514. doi:10.7326/M22-0318
- Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to
measure the factor Xa-inhibiting properties of apixaban–an oral,
direct and selective factor Xa inhibitor. J Thromb Thrombolysis.
2011;32:183-187. doi:10.1007/s11239-011-0591-8
- Eliquis [Label] Princeton, NJ: Bristol-Myers Squibb;
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
2012
- Eliquis [European Union Summary of product characteristics].
European Medicines Agency.
https://www.medicines.org.uk/emc/product/2878/smpc#gref. 2021.
- VanderPluym C, Esteso P, Ankola A, et al. Real-world use of apixaban
for the treatment and prevention of thrombosis in children with
cardiac disease [published online ahead of print, 2023 Mar 14]. J
Thromb Haemost. 2023;S1538-7836(23)00232-5.
doi:10.1016/j.jtha.2023.03.005
- Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and Safety of
Apixaban in over 3.9 Million People with Atrial Fibrillation: A
Systematic Review and Meta-Analysis. J Clin Med. 2022;11:3788.
Published 2022 Jun 30. doi:10.3390/jcm11133788
- Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of
a Heparin-Calibrated Antifactor Xa Assay for Measuring the
Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb
Hemost. 2016;22(5):423-428. doi:10.1177/1076029616629759
- Bercovitz RS, Shewmake AC, Newman DK, et al. Validation of a
definition of excessive postoperative bleeding in infants undergoing
cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg.
2018;155:2112-2124.e2. doi:10.1016/j.jtcvs.2017.12.038
- Moganasundram S, Hunt BJ, Sykes K, et al. The relationship among
thromboelastography, hemostatic variables, and bleeding after
cardiopulmonary bypass surgery in children. Anesth Analg.
2010;110:995-1002. doi:10.1213/ANE.0b013e3181cd6d20
- Niebler RA, Gill JC, Brabant CP, et al. Thromboelastography in the
assessment of bleeding following surgery for congenital heart disease.
World J Pediatr Congenit Heart Surg. 2012;3:433-438.
doi:10.1177/2150135112447540
- Agarwal HS, Barrett SS, Barry K, et al. Association of blood products
administration during cardiopulmonary bypass and excessive
post-operative bleeding in pediatric cardiac surgery. Pediatr Cardiol.
2015;36:459-467. doi:10.1007/s00246-014-1034-z
- Pekelharing J, Furck A, Banya W, Macrae D, Davidson SJ. Comparison
between thromboelastography and conventional coagulation tests after
cardiopulmonary bypass surgery in the paediatric intensive care unit.
Int J Lab Hematol. 2014;36:465-471. doi:10.1111/ijlh.12171
- Timpa JG, O’Meara LC, Goldberg KG, et al. Implementation of a
Multidisciplinary Bleeding and Transfusion Protocol Significantly
Decreases Perioperative Blood Product Utilization and Improves Some
Bleeding Outcomes. J Extra Corpor Technol. 2016;48:11-18.
- Faraoni D, Van der Linden P. Factors affecting postoperative blood
loss in children undergoing cardiac surgery. J Cardiothorac Surg. 2014
Feb 11;9:32. doi: 10.1186/1749-8090-9-32. PMID: 24512988; PMCID:
PMC3924411.
- Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-Analysis of
Reversal Agents for Severe Bleeding Associated With Direct Oral
Anticoagulants. J Am Coll Cardiol. 2021;77:2987-3001.
doi:10.1016/j.jacc.2021.04.061